A. Y. Pavliskyi
Research Subjects
A. Y. Pavliskyi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mykyta Bielinskyi
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
1 shared publication - N. B. Nyshchuk-Oliinyk
Івано-Франківський національний медичний університет
1 shared publication - O. O. Tkachuk-Hryhorchuk
Івано-Франківський національний медичний університет, Україна
1 shared publication - Oksana Didushko
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
1 shared publication - Serhii Herashchenko
Івано-Франківський національний медичний університет
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Open AccessAdjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.